Agonistas de GLP-1 más inhibidores de SGLT2. ¿Efectos cardioprotectores aditivos?

Gabriel Jaime Matta-Herrera, Luis Manuel Ballestas-Alarcón, Alex Ramírez-Rincón

Producción científica: Contribución a una revistaArtículo en revista científica indexadarevisión exhaustiva

2 Citas (Scopus)

Resumen

In South America, Colombia is secondly with number of diagnosed patients with diabetes mellitus (DM) and probably non-diagnostic patients. It has been calculated in Colombia 2 million people with diabetes mellitus, with a prevalence of 9.6% and it is the fifth position of causes of death and within the 10 causes that motivate the search for help. The new therapies with glucagon-like-1 receptors agonists (GLP-1 RAs) and SGLT2 inhibitors (SGLT2i) have been shown individually and through different mechanisms of action impact on the metabolic control and other variables such as blood pressure, lipid profile, weight, renal and cardiovascular protection. Type 2 diabetes mellitus treatment guides recommend for patients with dual therapy who continue HA1c out of goals, consider triple therapy if the patient has not achieved the goals after three months. A systematic search was made that included search engines such as Pubmed, Embase and Cochrane, resulting in 12 articles. More clinical studies should be done with the combination of GLP-1 RAs and SGLT2i in the context of patients with type 2 diabetes mellitus with poor metabolic control despite dual and triple therapies.

Título traducido de la contribuciónGLP-1 agonists plus SGLT2 inhibitors. Additive cardioprotective effects?
Idioma originalEspañol
Páginas (desde-hasta)601-613
Número de páginas13
PublicaciónMedicina Interna de Mexico
Volumen34
N.º4
DOI
EstadoPublicada - 1 jul. 2018
Publicado de forma externa

Palabras clave

  • Glucagon
  • Type 2 diabetes mellitus

Tipos de Productos Minciencias

  • Artículos de investigación con calidad A1 / Q1

Huella

Profundice en los temas de investigación de 'Agonistas de GLP-1 más inhibidores de SGLT2. ¿Efectos cardioprotectores aditivos?'. En conjunto forman una huella única.

Citar esto